The Ten Percent Margin Is A Write Down, Not The Business

Generated used Opus 5. Not the opinion of the author.

Start by correcting the margin. Screens show Colgate earning about 10% net. Full year 2025 net income fell to $2.13 billion from $2.89 billion, primarily because of a $794 million non-cash impairment on goodwill and intangibles in the skin health business, driven by underperformance in China. Add it back and the margin is roughly 14.3%, in line with 2024's 14.4%. Base Business EPS rose 3% to $3.69 while GAAP EPS fell 25% to $2.63. Cash was never touched: operating cash flow set a record at $4.198 billion.

The distortion runs through every derived metric. The dividend payout looks stretched at roughly 82% of GAAP EPS and is about 57% of Base Business EPS. The stock looks expensive at 35 times GAAP earnings and trades near 24 times normalised. The trailing twelve month margin carries the same contamination, because the fourth quarter of 2025 still sits inside the window.

This creates a trap worth naming. If you normalise the margin but leave the future multiple at the GAAP-derived figure, you count the adjustment twice and overstate fair value by roughly 45%. The margin and the multiple have to sit on the same basis. That is why 15% pairs with 24x here rather than with 35x.

The operating business is running ahead of the tape. Second quarter net sales rose 4.9% to $5.36 billion with organic sales up 2.4%, Base Business EPS up 8% to $0.99, and gross margin up 140 basis points to 61.5%. That extended the earnings beat streak to five quarters, with volume growth accelerating for a third consecutive quarter. Free cash flow rose 18% through the first half, and management raised full year gross margin guidance to roughly flat against a prior expectation of decline, while increasing advertising at a double digit rate.

The weakness is geographic. North America organic sales fell 3.0% on weaker volumes and retailer destocking, and management said the recovery there will be gradual rather than linear. Against that, emerging markets grew mid single digits on strength in India, Brazil, Mexico and China, and the Strategic Growth and Productivity Program targets $200 million to $300 million of annual pretax savings. A business holding 41.3% of the global toothpaste market and 32.7% of manual toothbrushes can absorb one weak region. What it cannot absorb is losing the category.

Why 4% growth. Full year guidance is net sales up 2% to 6%, organic 1% to 4%, against a long term target of 3% to 5% organic. Net sales grew 1.4% in 2025, and the first half of 2026 benefited materially from currency rather than volume. Four percent is the midpoint of guidance and assumes organic settles near 3% with pricing and mix on top. It does not assume North America recovers quickly.

Why a 15% margin. Normalised 2025 was about 14.3% and 2024 was 14.4%. The productivity programme is worth roughly a point of pretax margin at current revenue, but much of it is being reinvested in advertising, and tariffs, freight and management's warning about oil near $90 a barrel all push the other way. Fifteen percent assumes roughly half a point of net expansion over five years. At 14.5% the output falls to about $84.

Why 24x. This is where Colgate trades on normalised earnings, and it is consistent with its history as a defensive compounder. It is the input most likely to be pre-populated wrongly, for the reason described above.

Why 7%. A staples business with those category shares and $3.77 billion of trailing free cash flow carries a low cost of equity. Net debt of $6.55 billion is real but modest against that generation. Worth noting: at a 6% discount this model returns $90.64, almost exactly the current price. The market is effectively discounting Colgate at 6% on these fundamentals.

A note on the shape of this result. Twenty four times forward Base Business earnings of roughly $3.88 implies about $93 today. This model returns $86.48. The whole difference is structural. When the discount rate exceeds the growth rate, five years at a three point gap costs about 16%. For a slow compounder this method is inherently more conservative than a simple multiple, and that is worth knowing before treating the output as a verdict rather than as one lens.

What today's price requires

At the same 7% discount, justifying $90.80 needs roughly 4% growth with a 25x exit, or 5% growth at 24x, or a 15.5% margin at 4% growth. Every one of those is ordinary. Colgate is not priced for a transformation. It is priced for competent continuation, and the gap to this narrative is about 5%.

What kills this thesis

North American organic sales still negative by the second quarter of 2027. Gross margin failing to hold flat for full year 2026 after guidance was raised. Organic growth landing below the 1% floor. A further impairment in skin health, which would mean the 2025 charge understated the problem rather than resolved it. Emerging market growth slipping below mid single digits, since that is currently carrying the company.

Checkpoints

Third quarter 2026, which management describes as largely locked in: whether gross margin expansion holds. Fourth quarter 2026: the oil price effect management flagged, and whether full year organic lands inside guidance. Through 2027: North American organic returning to positive, and productivity savings appearing in reported margin rather than being fully reinvested.